SCHEMBL900225

SCHEMBL900225

c1ccc(C2CC2)nc1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29448519 1.00
SCHEMBL659325 1.00 KDM4E (0.48)
Formaldehyde SCHEMBL28000054 0.93 ALDH1A1 (0.47)
Cyanide SCHEMBL27321964 0.93 ALDH1A1 (0.42)
SCHEMBL1515110 0.91 ALDH1A1 (0.46)
SCHEMBL1481510 0.91 ALDH1A1 (0.50)
SCHEMBL9999607 0.89 ALDH1A1 (0.44)
SCHEMBL14619610 0.89 ALDH1A1 (0.44)
SCHEMBL30066891 0.89 PDE10A (0.45)
SCHEMBL26242789 0.89 HSD11B1 (0.41)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 371 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230219954-A1 P2X3 AND/OR P2X2/3 COMPOUNDS AND METHODS ASANA BIOSCIENCES, LLC 2023-07-13 US claimed
US-11685736-B2 P2X3 and/or P2X2/3 compounds and methods ABS DEVELOPMENT 1, INC. (US) 2023-06-27 US claimed
EP-3083619-B1 P2X3 AND/OR P2X2/3 COMPOUNDS AND METHODS ASANA BIOSCIENCES LLC (US) 2021-11-03 EP claimed
US-20200109143-A1 P2X3 AND/OR P2X2/3 COMPOUNDS AND METHODS ABS DEVELOPMENT 1, INC. 2020-04-09 US claimed
US-10544145-B2 P2X3 and/or P2X2/3 compounds and methods ASANA BIOSCIENCES, LLC (US) 2020-01-28 US claimed
US-20190248789-A1 P2X3 AND/OR P2X2/3 COMPOUNDS AND METHODS ABS DEVELOPMENT 1, INC. 2019-08-15 US claimed
CN-105517996-B Therapeutical active compound and its application method 安吉奥斯医药品有限公司 2019-03-26 CN claimed
CN-108912066-A Therapeutical active compound and its application method 安吉奥斯医药品有限公司 2018-11-30 CN claimed
EP-3363788-A1 CANNABINOID RECEPTOR MODULATORS Arena Pharmaceuticals, Inc. (US) 2018-08-22 EP claimed
US-20180186793-A1 P2X3 AND/OR P2X2/3 COMPOUNDS AND METHODS ABS DEVELOPMENT 1, INC. 2018-07-05 US claimed
EP-2470508-A1 CANNABINOID RECEPTOR MODULATORS Arena Pharmaceuticals, Inc. (US) 2012-07-04 EP claimed
WO-2012072713-A2 LYSINE DEMETHYLASE INHIBITORS FOR DISEASES AND DISORDERS ASSOCIATED WITH FLAVIVIRIDAE ORYZON GENOMICS, S.A. (ES) 2012-06-07 WO claimed
WO-2012042042-A1 SELECTIVE LSD1 AND DUAL LSD1/MAO-B INHIBITORS FOR MODULATING DISEASES ASSOCIATED WITH ALTERATIONS IN PROTEIN CONFORMATION ORYZON GENOMICS S.A. (ES) 2012-04-05 WO claimed
WO-2011025541-A1 CANNABINOID RECEPTOR MODULATORS ARENA PHARMACEUTICALS, INC. (US) 2011-03-03 WO claimed
CN-101678011-A Spiro-indolinone compounds MERCK & CO INC 2010-03-24 CN claimed
EP-1056771-B1 STREPTOGRAMIN DERIVATIVES, PREPARATION METHOD AND COMPOSITIONS CONTAINING SAME AVENTIS PHARMA SA (FR) 2005-11-30 EP claimed
JP-2002504560-A 2002-02-12 JP claimed
CN-1290270-A Streptogramin derivatives, preparation method and compositions containing them AWENTIS PHARMACEUTICS S A (FR) 2001-04-04 CN claimed
EP-1056771-A1 STREPTOGRAMIN DERIVATIVES, PREPARATION METHOD AND COMPOSITIONS CONTAINING SAME Aventis Pharma S.A. (FR) 2000-12-06 EP claimed
WO-1999043699-A1 STREPTOGRAMIN DERIVATIVES, PREPARATION METHOD AND COMPOSITIONS CONTAINING SAME AVENTIS PHARMA S.A. (FR) 1999-09-02 WO claimed